KRAS-Targeted Drugs: From Molecular Discovery to Clinical Application Introduction KRAS is one of the most important oncogenic drivers in human cancer. It belongs to the RAS family of small GTPases. These proteins regulate cell growth, survival and proliferation. For decades, KRAS was considered difficult to target with drugs. Scientists struggled to find suitable binding sites […]
Tag: Anticancer Drugs
Analysis of Immune Checkpoint Inhibitor Efficacy in Mesothelioma Immune checkpoint inhibitors have changed treatment approaches for several cancers. Researchers now examine their effectiveness in mesothelioma. Studies stratify results by PD-L1 expression and histological subtype. This analysis helps identify which patients benefit most. PD-L1 expression serves as a key biomarker. Higher PD-L1 levels often correlate with […]
In this article we will discuss Cytoreductive Surgery and HIPEC in Peritoneal Malignancies
In this article we will discuss Oncogenic Signaling Pathways: PI3K/AKT/mTOR
CAR-T therapy has transformed treatment for certain blood cancers. However, solid tumours present greater challenges. The immunosuppressive microenvironment and limited T-cell trafficking reduce effectiveness. Researchers therefore develop multiple strategies to overcome these barriers. Solid tumours create a hostile local environment. Dense stroma, low oxygen levels, and inhibitory molecules restrict CAR-T cell function. Regulatory immune cells […]
Study Reveals Gaps in Oncology Guideline Adherence Across Tertiary Cancer Centers Researchers examined adherence to oncology patient care guidelines in major tertiary cancer centers. They compared national standards from ICMR and NCI-India with international ones from ASCO, ESMO, and NCCN. The analysis focused on how closely doctors followed these guidelines. It also measured links to […]